0A8R Stock Overview
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0A8R from our risk checks.
Seagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$228.95 |
| 52 Week High | US$228.95 |
| 52 Week Low | US$126.34 |
| Beta | 0.32 |
| 11 Month Change | 7.57% |
| 3 Month Change | 10.21% |
| 1 Year Change | 81.13% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 57.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A8R | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.6% | 2.0% | 1.7% |
| 1Y | 81.1% | -17.5% | 8.3% |
Return vs Industry: 0A8R exceeded the UK Biotechs industry which returned -27.1% over the past year.
Return vs Market: 0A8R exceeded the UK Market which returned -3.1% over the past year.
Price Volatility
| 0A8R volatility | |
|---|---|
| 0A8R Average Weekly Movement | 1.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A8R has not had significant price volatility in the past 3 months.
Volatility Over Time: 0A8R's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3,256 | David Epstein | www.seagen.com |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases.
Seagen Inc. Fundamentals Summary
| 0A8R fundamental statistics | |
|---|---|
| Market cap | US$43.15b |
| Earnings (TTM) | -US$750.22m |
| Revenue (TTM) | US$2.30b |
18.8x
P/S Ratio-57.5x
P/E RatioIs 0A8R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A8R income statement (TTM) | |
|---|---|
| Revenue | US$2.30b |
| Cost of Revenue | US$2.13b |
| Gross Profit | US$171.59m |
| Other Expenses | US$921.81m |
| Earnings | -US$750.22m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.98 |
| Gross Margin | 7.46% |
| Net Profit Margin | -32.61% |
| Debt/Equity Ratio | 0% |
How did 0A8R perform over the long term?
See historical performance and comparison